Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon alfa-2b +/- bevacizumab in advanced renal cell carcinoma
NCT00072046Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Oct 2003
- Primary completion
- Jan 2004
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of bevacizumab in renal cell carcinoma (RCC), sponsored by Cancer and Leukemia Group B. Started Oct 2003; status: completed.
02
Drugs
bevacizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00072046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00072046.